| Literature DB >> 16230187 |
Olivier Lambotte1, Moana Gelu-Simeon, Gwenola Maigne, Rami Kotb, Catherine Buffet, Jean François Delfraissy, Cécile Goujard.
Abstract
In this report, we describe an unusual and unreported complication with the new licensed form of pegylated interferon alpha2a (PEG-IFN-alpha2a). We report the first case of severe autoimmune cytopenias, an Evans' syndrome, in a patient with chronic hepatitis C, 2 months after PEG-IFN-alpha2a initiation. Haemolytic anaemia and thrombocytopenia developed, complicated by gastric bleeding and brain haemorrhage. Outcome was favourable under immunosuppressive treatment. Treatment with PEG-IFN-alpha2a requires careful follow-up, as IFNalpha can induce or exacerbate autoimmune diseases.Entities:
Mesh：
Substances：
Year: 2004 PMID： 16230187 DOI： 10.1016/j.jinf.2004.10.010
Source DB: PubMed Journal: J Infect ISSN： 0163-4453 Impact factor: 6.072